European Industrial Pharmacists Group

IDAP, the IFPMA’s vision of innovation development and access pathways

The International Federation of Pharmaceutical Manufacturers and Associations proposed the IDAP (Innovation Development and Access Pathway) framework to streamline and, as far as possible, harmonise pathways for ensuring rapid authorisation and access to innovative medicines and vaccines, taking into account the specific characteristics of different countries.

Presentations

Our media library contains an extensive collection of presentations by EIPG Bureau members or delegates, and presentations made at Scientific Symposia.

News from EIPG

The latest news on EIPG activities, events and publications.

Position Papers

EIPG issues comments and feedback in response to consultation documents and white papers released by the European Medicines Agency and the European Commission.

Guides and Codes

Read through our guides and codes of practice issued as guidance to industrial pharmacists.

Education

EIPG’s initiatives dedicated to industrial pharmacist education, including the EU-funded projects MOGLYNET, PHAR-IN and PHARMINE.

Members’ Area

Member organisations can sign in here to get even more information regarding EIPG’s projects and works.

2026 trends in pharmaceutical development

The introduction of artificial intelligence is one of the main drivers that will support the pharmaceutical industry’s final steps towards more innovative models, while facing legislative and regulatory innovation and geopolitical tensions. Biotech products are leading the way in innovative treatments

Many advancements in the setting up of the new pharmaceutical legislation

On 11 December 2025, the Trilogue reached an agreement on the final text of the “pharma package”, which includes the regulations and directives governing the development, production and commercialisation of medicinal products in the EU. The package now awaits formal adoption by the European Council and Parliament before it can enter into force. We summarise the main features of the reform of the European pharmaceutical legislation

Bacteriophages and AMR, the beginning of a new era?

The newly published EMA draft guideline on the quality aspects of phage therapy medicinal products paves the way for the use in Western Europe of this new - albeit century-old - approach to treating antibiotic-resistant infections

The EU Commission adopted the rules for JCAs of medical devices and in vitro diagnostics

The last of the six implementing regulations concerning HTA procedures was published on 17 October 2025. It describes the detailed procedures to perform the joint clinical assessment of medical devices and in vitro diagnostics

The UK’s new decentralised manufacturing framework

The new Decentralised Manufacturing Framework came into force on 23 July 2025. It enables the production of innovative medicines products such as cellular therapies close to the patients who will receive them. The framework covers both Point of Care manufacturing and Modular Manufacturing, and it requires prior authorisation and provides an alternative to traditional, centralised productions

The challenging roadmap to design the future of EU’s R&D

The ongoing debate on simplifying and standardising the rules for accessing EU research funding is in an hot phase. ERC president Maria Leptin rejected the Commission’s proposals, while the ERC Scientific Council published its new rules for the evaluation of scientific proposals. In a recent speech on the advancement of the Competitiveness Compass, Mario Draghi emphasised the need for a more proactive approach to priority programmes on critical technologies. He also drew attention to dual-use technologies, an approach combining civil and defence applications which has divided the EU Parliament